• Home
  • NEW DAY MEDICINE
  • 2(40)2022
  • 61 -2 (40) 2022 – Avdeeva M.G.,  Oblokulov A.R., – PROCALCITONIN AS A PREDICTOR OF ANTIBACTERIAL THERAPY FOR COVID-19

61 -2 (40) 2022 – Avdeeva M.G.,  Oblokulov A.R., – PROCALCITONIN AS A PREDICTOR OF ANTIBACTERIAL THERAPY FOR COVID-19

PROCALCITONIN AS A PREDICTOR OF ANTIBACTERIAL THERAPY FOR COVID-19

Avdeeva M.G.,   Kuban State Medical University Krasnodar, Russia Bukhara State Medical Institute named after Abu Ali ibn Sino Bukhara, Republic of Uzbekistan

Oblokulov A.R., Kuban State Medical University Krasnodar, Russia Bukhara State Medical Institute named after Abu Ali ibn Sino Bukhara, Republic of Uzbekistan

Ergashov M.M. Kuban State Medical University Krasnodar, Russia Bukhara State Medical Institute named after Abu Ali ibn Sino Bukhara, Republic of Uzbekistan

Resume

The article presents laboratory characteristics, as well as the potential of biomarkers to predict the severity of the disease in patients infected with SARS-CoV-2. 120 patients with a new coronavirus infection were examined. All patients had laboratory-confirmed SARS-CoV-2 infection. Patients were divided into severe patients (n=60) and patients with moderate forms (n=60). The median age was 53 years, and of the 120 patients, 96 (80%) were men.

The significance of procalcitonin as a biomarker for assessing the risk of bacterial infection, disease progression, timely prescription of antibacterial drugs and the duration of antibiotic therapy was studied.

Key words: SARS-CoV-2, COVID-19, gastrointestinal, neurological, skin manifestations, procalcitonin.

First page

321

Last page

325

For citation: Avdeeva M.G.,   Oblokulov A.R., Ergashov M.M. PROCALCITONIN AS A PREDICTOR OF ANTIBACTERIAL THERAPY FOR COVID-19 //New Day in Medicine 2(40)2022 321-325 https://cutt.ly/fAKGVr4

LIST OF REFERENCES:

  1. Lu H., Stratton C.W., Tang Y.-W.: Outbreak of pneumonia of unknown etiology in Wuhan, China: The mystery and the miracle. J. Med. Virol., 2020; 92: 401–402.
  2. Zhu N., Zhang D., Wang W.: A novel coronavirus from patients with pneumonia in China, 2019. N. Engl. J. Med., 2020; 382: 727–733.]
  3. Oblokulov A.R., Niyozov G.E. (2020) Clinical and epidemiological characteristics of patients with COVID-19. International Journal of Pharmaceutical Research; 12(4):3749-3752.
  4. Oblokulov A.R., Musaeva D.M., Elmuradova A.A. (2020) Clinical and epidemiological characteristics of the new coronavirus infection (COVID-19). // New Day in Medicine. №2 (30/2) p.110-115.
  5. Cao Y., Liu X., Xiong L. et al.  Imaging and clinical features of patients with 2019 novel coronavirus SARS‑CoV‑2: a systematic review and meta‑analysis. J. Med. Virol., 2020; doi: 10.1002/jmv.25 822.
  6. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34(7):1996–2003.
  7. Kutz A, Briel M, Christ-Crain M, et al. Prognostic value of procalcitonin in respiratory tract infections across clinical settings. Critical Care (London, England) 2015; 19 (1):74.
  8. Schuetz P, Wirz Y, Sager R, Christ-Crain M, Stolz D, Tamm M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev.2017;10:CD007498.  
  9. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130(5):2620-9.
  10. Heesom L, Rehnberg L, Nasim-Mohi M, Jackson AIR, Celinski M, Dushianthan A, et al. Procalcitonin as an antibiotic stewardship tool in COVID-19 patients in the intensive care unit. J Glob Antimicrob Resist. 2020; 22:782-4.
  11. Chen T, Wu D, Chen H, Yan W, Yang D, Chen G, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ. 2020; 368:m1091.
  12. Guan, W., Ni, Z., Hu, Y. et al.Clinical characteristics of 2019 novel coronavirus infection in China // N Engl J Med. 2020; 382 (18): 1708-1720.
  13. Williams E.J. et al. (2020) Routine measurement of serum procalcitonin allows antibiotics to be safely withheld in patients admitted to hospital with SARS-CoV-2 infection. medRxiv. doi. org/10.1101/2020.06.29.20136572.
  14. Niyazov G.E., Oblokulov A.R., Pondina A.I.et al. (2020) Clinical and epidemiological characteristics of COVID-19 patients   // New Day in Medicine. №4 (32) 110-115 p.
  15. Oblokulov, A. R., Husenova, Z. Z., & Ergashev, M. M. (2021). Procalcitonin as an indicator of antibacterial therapy in covid-19. Annals of the Romanian Society for Cell Biology, 5220-5224.
  16.   Elmurodova A. A. (2022) “Specific Features of the Hemostatic System in Covid-19”. CENTRAL ASIAN JOURNAL OF MEDICAL AND NATURAL SCIENCES 3, 82-85.
  17. Meisner M. Procalcitonin – biochemistry and clinical diagnosis. Bremen: UNI-MED; 2010. 128 p.

file

download